Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions

May 18 2022

• By Derrick Gingery

biologic — The Senate bill would address some biosimilar questions, but others still linger. • Source: Shutterstock

Related Content

Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement

Jul 13 2021

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 18 2020

Could US FDA User Fee Bill Include The Long-Sought 505(b)(2) Pathway For Biosimilars?

May 26 2021

Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill

May 02 2022

Is CREATES Act Equipped To Handle Biosimilar Complaints?

Jan 04 2022

US FDA Making BsUFA III Regulatory Science Grants Available Early

Mar 07 2022

Biosimilar Legislation Could Upend Interchangeability Rather Than Prevent Product Hopping

Mar 24 2022

Accelerated Approval, Clinical Trial Diversity Provisions Left Out Of Senate User Fee Bill

May 18 2022

Inactive Ingredient Disclosure Expansion In House User Fee Bill Poised For Changes

May 11 2022

Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs

Aug 04 2003

Additional Topics

United States Biosimilars User Fees Legislation Regulation Review Pathway Politics BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window